On Wednesday, June 6, 2018 at 8:30 a.m. Eastern Time, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company at Jefferies 2018 Global Healthcare Conference.Register Now
On Sunday, June 3, 2018 at 7:30 p.m. Central Time, Immunomedics will host an Investor Event where updates on sacituzumab govitecan in breast and other cancers will be provided by key opinion leaders and company executives.Register Now
We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.Our Science
We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.Learn More
Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.